
Valeant have hit the mainstream news again after key investor Bill Ackman mounted a robust defence of the company, ruling …
Major funding opportunity opens for early cancer diagnostics
Androlabs receives UK authorisation for new Testavan presentation
CEPI backs African-led Bundibugyo Ebola vaccine development
Cytomos appoints life sciences executive to board

